All In Biotech

Drug Trial Radar · NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,006

Planned (sponsor's estimate)

Start

Jun 8, 2020

Primary completion

Jun 16, 2027

Study completion Mar 22, 2029

Sponsor

Sponsor type
Industry
First posted
May 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs. * Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors. * In Parts C and D, participants will receive sigvotatug vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin.

Conditions

  • Carcinoma, Non-Small Cell Lung
  • Squamous Cell Carcinoma of Head and Neck
  • HER2 Negative Breast Neoplasms
  • Esophageal Squamous Cell Carcinoma
  • Esophageal Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Ovarian Neoplasms
  • Cutaneous Squamous Cell Cancer
  • Exocrine Pancreatic Adenocarcinoma
  • Urinary Bladder Neoplasms
  • Uterine Cervical Neoplasms
  • Stomach Neoplasms

Interventions

  • sigvotatug vedotinDrug

    Administered into the vein (IV; intravenously)

  • pembrolizumabDrug

    200mg every 3 weeks or 400mg every 6 weeks, given by IV

  • cisplatinDrug

    75 mg/m2 every 3 weeks, given by IV

  • carboplatinDrug

    AUC 5 mg/mL per min every 3 weeks, given by IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years
  2. Number of patients with laboratory abnormalitiesTime frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
  3. Number of participants with dose-limiting toxicities (DLTs)Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

Locations

158 sites in 7 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology

    Anchorage, Alaska · Recruiting

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Providence Medical Foundation

    Anaheim, California · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • Providence St. Jude Medical Center Virginia K Crosson and Infusion Center

    Fullerton, California · Recruiting

  • Cancer and Blood Research Center, LLC

    Los Alamitos, California · Not yet recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Not yet recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • The Regents of the University of California

    Los Angeles, California · Recruiting

  • UCLA Department of Medicine-Hematology/Oncology

    Los Angeles, California · Recruiting

  • UCLA Department of Medicine - Hematology & Oncology

    Santa Monica, California · Recruiting

  • Cancer AND Blood Specialty Clinic

    Torrance, California · Not yet recruiting

  • American Oncology Partners, PA. a Florida professional service corporation, d/b/a Vista Oncology

    Fort Myers, Florida · Recruiting

  • Florida Cancer Specialists & Research Institute, LLC

    Fort Myers, Florida · Recruiting

  • Memorial Cancer Institute

    Hollywood, Florida · Recruiting

  • Memorial Healthcare System

    Hollywood, Florida · Recruiting

  • Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • Memorial Cancer Institute at Memorial Hospital West

    Pembroke Pines, Florida · Recruiting

  • Memorial Hospital West

    Pembroke Pines, Florida · Recruiting

  • Ingalls Family Care Center

    Calumet City, Illinois · Recruiting

  • UChicago Medicine - River East

    Chicago, Illinois · Recruiting

  • The University Of Chicago

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • UChicago Medicine at Ingalls - Flossmoor

    Flossmoor, Illinois · Recruiting

  • UChicago Medicine Ingalls Memorial

    Harvey, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital

    New Lenox, Illinois · Recruiting

  • The University of Chicago Medicine Center for Advanced Care Orland Park

    Orland Park, Illinois · Recruiting

  • Southern Illinois University - Simmons Cancer Institute

    Springfield, Illinois · Recruiting

  • Springfield Clinic Radiology - 800 Building

    Springfield, Illinois · Recruiting

  • Springfield Clinic Urgent Care Plus

    Springfield, Illinois · Recruiting

  • Springfield Clinic

    Springfield, Illinois · Recruiting

  • Springfield Clinic Main Campus

    Springfield, Illinois · Recruiting

  • Springfield Clinic Radiology - Main Campus

    Springfield, Illinois · Recruiting

  • Springfield Memorial Hospital

    Springfield, Illinois · Recruiting

  • UChicago Medicine at Ingalls - Tinley Park

    Tinley Park, Illinois · Recruiting

  • UChicago Medicine - Northwest Indiana

    Crown Point, Indiana · Recruiting

  • Fort Wayne Medical Oncology and Hematology, Inc

    Fort Wayne, Indiana · Recruiting

  • Community Health Network, Inc

    Indianapolis, Indiana · Recruiting

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.